[Cisapride and sucralfate in dyspepsia associated with duodenogastric reflux gastritis].
The present investigation was undertaken with the aim of evaluating the clinical efficacy on dyspeptic symptoms associated with duodenogastric reflux gastritis of two drugs belonging to two different groups: a prokinetic (cisapride) and a cytoprotective agent (sucralfate). A total of 18 patients with duodenogastric reflux gastritis diagnosed on the basis of symptoms, endoscopy and histology were studied. Nine were given 30 mg of cisapride/daily and 9 4 g of sucralfate/daily for two months according to a randomization list. Pyrosis, epigastric pain, sense of epigastric repletion and foul-tasting mouth were considered on a scale from 0 to 4 attributed by the patient. The total score of dyspeptic symptoms significantly decreased only after cisapride (p less than 0.05). Considering each symptom alone, neither cisapride or sucralfate were able to significantly improve them. Cisapride seems to the better than sucralfate in improving dyspeptic symptoms associated with duodeno-gastric reflux gastritis.
Scalon
P
P
Istituto di Medicina Interna, Università degli Studi di Padova.
Di Mario
F
F
Meggiato
T
T
Basso
D
D
Battaglia
G
G
Vianello
F
F
Fogar
P
P
Del Favero
G
G
D000328:Adult; D000368:Aged; D020117:Cisapride; D004383:Duodenogastric Reflux / Q000150:complications* / Q000175:diagnosis; D004415:Dyspepsia / Q000188:drug therapy* / Q000209:etiology; D004724:Endoscopy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D013392:Sucralfate / Q000627:therapeutic use*
D010880:Piperidines; D012702:Serotonin Antagonists; D013392:Sucralfate; D020117:Cisapride